Clinical Trial Update: Fluselenamyl - Beta Amyloid PET Imaging for Alzheimer Disease

View source ↗

Summary

Clinical trial update for Fluselenamyl as a beta-amyloid PET imaging agent in Alzheimer's disease. The study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Fluselenamyl (Fluselenamyl)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Alzheimer Disease | Status: ACTIVE_NOT_RECRUITING